Microdosing LSD is repeated use of a hallucinogenic drug at doses too small to cause noticeable effects, pursued for steadier mood, sharper focus and a more resilient aging brain. Controlled studies show brief effects, not lasting gains; no benefit reaches the highest evidence level. Best-supported findings are side effects: anxiety, physical discomfort, small blood pressure rises, slightly reduced attention control. Whether effects reflect the drug or expectation remains open. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure (seated, resting) | Below 120/80 mmHg | Rose at 10-20 µg |
| Resting heart rate | 50-70 beats per minute | Rose under 15% at 10 µg; marks stimulant load |
| Echocardiogram (heart-valve ultrasound) | No new or worsening valve regurgitation versus baseline | Related drugs caused valve scarring through the serotonin 2B receptor |
| Electrocardiogram | No established LSD-specific target; track corrected QT interval and rhythm change from baseline | Used as safety measure in a patient trial |
| Liver enzymes (ALT, AST) | ALT at or below 25 U/L | LSD is cleared by liver enzymes |
| CYP2D6 genotype (one-time) | No optimal target; note metabolizer status | Poor metabolizers had about 75% higher exposure |
| Mood and anxiety questionnaire scores | No established target; track change from own baseline (lower is better) | Anxiety is the leading adverse event; tests claimed benefit |
| Sleep duration (wearable) | 7-9 hours per night; track change from baseline | The one controlled sleep signal was +24 minutes |
Cadence: Baseline first; blood pressure, heart rate, mood scores and sleep at 1, 4 and 8 weeks, then every 3 months; ultrasound and liver enzymes after 6-12 months, then yearly